Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Atropan-D
- Development stage
- Phase 4
- Lead developer
- Atro Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Atropan-D is an oral sustained-release combination capsule developed by Atro Pharma for the treatment of gastrointestinal disorders. It contains 40mg of pantoprazole, a proton pump inhibitor that reduces gastric acid secretion by inhibiting the H+/K+-ATPase enzyme, and 30mg of domperidone, a dopamine D2 receptor antagonist that acts as a prokinetic agent to enhance gastric emptying and provide antiemetic effects. The drug is indicated for gastroesophageal reflux disease (GERD), erosive esophagitis, gastritis, and peptic ulcers, particularly when associated with symptoms like nausea, bloating, and heartburn. It is currently approved and marketed in India.
- Brand names
- Atropan-DAtropan D
- Other names
- domperidone + pantoprazole
02
Targets
ATP4A (Potassium–transporting ATPase alpha chain 1)
Beyond the preview
Go deeper on Atropan-D.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Atropan-D.